{
  "version": "https://jsonfeed.org/version/1.1",
  "title": "Biotech411",
  "home_page_url": "https://biotech411.com/",
  "feed_url": "https://biotech411.com/feed.json",
  "items": [
    {
      "id": "https://biotech411.com/editions/2026-11-21/#cber-safety-council",
      "url": "https://biotech411.com/editions/2026-11-21/#cber-safety-council",
      "external_url": "https://www.fda.gov/vaccines-blood-biologics/whats-new-biologics/fda-establishes-cber-safety-council-strengthen-postmarketing-oversight-biological-products",
      "title": "FDA forms a safety council to follow biologics after approval",
      "content_text": "The council will oversee postmarket safety across CBER products, including cell and gene therapies and blood products.",
      "tags": [
        "Regulatory policy"
      ],
      "_source": {
        "name": "FDA",
        "publication_date": "2026-11-19"
      }
    },
    {
      "id": "https://biotech411.com/editions/2026-11-21/#infilbray-gaucher",
      "url": "https://biotech411.com/editions/2026-11-21/#infilbray-gaucher",
      "external_url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-neurological-symptoms-type-3-gaucher-disease",
      "title": "Infilbray wins approval for neurological symptoms of type 3 Gaucher disease",
      "content_text": "FDA cleared venglustat for adults and children weighing at least 15 kg after a study compared it with enzyme replacement therapy.",
      "tags": [
        "Rare disease"
      ],
      "_source": {
        "name": "FDA",
        "publication_date": "2026-11-18"
      }
    },
    {
      "id": "https://biotech411.com/editions/2026-11-21/#lembaz-niemann-pick",
      "url": "https://biotech411.com/editions/2026-11-21/#lembaz-niemann-pick",
      "external_url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer",
      "title": "FDA clears Lembaz for infantile-onset Niemann-Pick type C",
      "content_text": "The indication covers reducing mortality risk in patients weighing at least 7 kg whose neurological symptoms began before age six.",
      "tags": [
        "Rare disease"
      ],
      "_source": {
        "name": "FDA",
        "publication_date": "2026-11-17"
      }
    },
    {
      "id": "https://biotech411.com/editions/2026-11-21/#rybrevant-head-neck",
      "url": "https://biotech411.com/editions/2026-11-21/#rybrevant-head-neck",
      "external_url": "https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-amivantamab-and-hyaluronidase-lpuj-recurrent-or-metastatic-head-and",
      "title": "Rybrevant Faspro gains a head and neck cancer indication",
      "content_text": "FDA granted accelerated approval after prior platinum chemotherapy and PD-(L)1 treatment, excluding HPV-associated oropharyngeal tumors.",
      "tags": [
        "Oncology"
      ],
      "_source": {
        "name": "FDA",
        "publication_date": "2026-11-05"
      }
    },
    {
      "id": "https://biotech411.com/editions/2026-11-21/#jemperli-rectal-cancer",
      "url": "https://biotech411.com/editions/2026-11-21/#jemperli-rectal-cancer",
      "external_url": "https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-dostarlimab-locally-advanced-rectal-cancer",
      "title": "FDA grants accelerated approval for Jemperli in a subset of rectal cancers",
      "content_text": "The new indication covers adults with stage II or III locally advanced tumors that are MSI-high or mismatch-repair deficient.",
      "tags": [
        "Oncology"
      ],
      "_source": {
        "name": "FDA",
        "publication_date": "2026-10-19"
      }
    },
    {
      "id": "https://biotech411.com/editions/2026-11-21/#gsd-phase-three-results",
      "url": "https://biotech411.com/editions/2026-11-21/#gsd-phase-three-results",
      "external_url": "https://clinicaltrials.gov/study/NCT05139316?tab=results",
      "title": "Glycogen storage disease trial posts its phase 3 results",
      "content_text": "The DTX401-CL301 registry record now includes the results tables underlying the program’s evaluation of daily cornstarch intake.",
      "tags": [
        "Trial results"
      ],
      "_source": {
        "name": "ClinicalTrials.gov",
        "publication_date": "2026-10-14"
      }
    },
    {
      "id": "https://biotech411.com/editions/2026-11-21/#fayuvi-sanfilippo",
      "url": "https://biotech411.com/editions/2026-11-21/#fayuvi-sanfilippo",
      "external_url": "https://www.fda.gov/vaccines-blood-biologics/fayuvi",
      "title": "Fayuvi gains approval for pediatric Sanfilippo syndrome type A",
      "content_text": "The indication covers neurological manifestations in children whose neurodevelopmental function is preserved.",
      "tags": [
        "Rare disease"
      ],
      "_source": {
        "name": "FDA",
        "publication_date": "2026-09-17"
      }
    }
  ]
}
